Tradestie Institutional Equity Comparison Engine

CRSP vs KYMR โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CRSP Overall Edge

CRSP Captures Institutional Edge (2โ€“2 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CRISPR Therapeutics AG (CRSP) driven by superior Valuation, Growth & Margin while KYMR counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, CRSP trades at 23.4x Forward P/E with -2058.6% operating margin (+1325.1% YoY revenue) versus KYMR at N/M Forward P/E and -396.0% operating margin (+466.4% YoY). In options structure, CRSP sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro) against KYMR sits in CONSOLIDATION (23rd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CRSP
CRSP 23.4x vs KYMR N/M Fwd P/E
Growth & Margin Winner CRSP
Op Margin -2058.6% vs -396.0% ยท YoY +1325.1% vs +466.4%
Momentum & Technical Winner KYMR
1Y -20.5% vs +96.1% ยท 52W Pos 1% vs 78%
Options & Structure Winner KYMR
BREAKDOWN (52nd %ile IV) vs CONSOLIDATION (23rd %ile IV)
CRSP NASDAQ
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
1M Return -17.54%
1Y Return -20.54%
Forward P/E 23.4x
Unified AI Score
48.6 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 68.0 Mom 60.0
KYMR NASDAQ
Kymera Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$124.79
-2.18% 1D
Market Cap $10.9B
1M Return +19.1%
1Y Return +96.12%
Forward P/E N/M
Unified AI Score
47.2 / 100 HOLD
Tech 36.0 Fund 51.0 Flow 67.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CRSP -20.54% KYMR +96.12% Spread: +116.66 pp (KYMR Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CRSP Revenue KYMR Revenue CRSP Op. Margin KYMR Op. Margin Margin Edge
FY2018 $0M N/A -5087.8% N/A CRSP
FY2019 $290M $0M 16.1% -1438.5% CRSP
FY2020 $0M $30M -49295.5% -136.1% KYMR
FY2021 $910M $70M 40.8% -138.0% CRSP
FY2022 $0M $50M -56190.4% -344.4% KYMR
FY2023 $370M $80M -60.0% -210.6% CRSP
FY2024 $40M $50M -1250.4% -555.8% KYMR
FY2025 $0M $40M -18933.6% -891.1% KYMR

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CRSP (5) vs KYMR (4)
Institutional Metric CRSP KYMR Criterion Row Winner
Market Capitalization Scale $4.1B $10.9B Larger Scale KYMR
Trailing P/E Ratio Valuation 23.4x N/M Lower Multiple CRSP
Forward P/E Ratio Valuation 23.4x N/M Lower Multiple CRSP
Revenue Growth (YoY) Growth +1325.1% +466.4% Higher Growth CRSP
Operating Margin (TTM) Profitability -2058.6% -396.0% Higher Margin KYMR
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -25.6% -27.3% Higher ROE CRSP
52-Week Range Position Momentum 1% ($40โ€“$63) 78% ($62โ€“$143) Stronger Trend KYMR
Beta / 30D Volatility Risk Regime 1.85ฮฒ ยท 60% Vol 1.04ฮฒ ยท 54% Vol Lower Realized Risk KYMR
Unified Institutional Score Composite Signal 48.6 / 100 (HOLD) 47.2 / 100 (HOLD) Higher Composite CRSP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CRSP vs KYMR Buy Guide
CRSP BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CRSP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
KYMR CONSOLIDATION
62d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 23rd %ile
IV Regime Compressed (<25th %ile)
Live KYMR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CRSP nor KYMR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.